Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.64Last Year’s EPS
-0.55Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 0.30%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the growth of global sales, successful Phase 3 trial results, and strong demand for IMCIVREE. However, challenges such as revenue impacts due to inventory shifts and patient discontinuations were noted. The company's financial position remains robust with a cash runway projected into 2027.Company Guidance
On the Rhythm Pharmaceuticals First Quarter 2025 Earnings Conference Call, the company provided positive guidance on their ongoing projects and future outlook. CEO David Meeker confirmed that they are on track for a Q3 filing for their Phase 3 trial on acquired hypothalamic obesity. The trial showed a 16.5% reduction in BMI for the setmelanotide cohort compared to a 3.3% increase in the placebo group, yielding a placebo-adjusted difference of 19.8%. The company also reported solid commercial performance for their product, IMCIVREE, with a 14% increase in global patients on reimbursed therapy. Internationally, the BBS launch is progressing well, contributing to revenue growth, particularly in France and Italy. Financially, Rhythm ended the quarter with $314.5 million in cash, projecting a cash runway into 2027. Additionally, they are looking forward to upcoming data readouts, including the bivamelagon Phase 2 results in Q3 and updates on their Prader-Willi and RM-718 studies by year-end. Overall, the company feels well-positioned with a strong pipeline and ongoing commercial success.Global Sales Revenue Growth
Revenue from global sales of IMCIVREE was $37.7 million in the first quarter of 2025, with the number of patients on reimbursed therapy increasing 14% globally during the quarter.
Phase 3 Trial Results for Setmelanotide
Phase 3 study showed a 16.5% reduction in BMI in the setmelanotide cohort compared to a 3.3% increase in BMI in the placebo group, for a placebo-adjusted difference of 19.8%.
Demand for IMCIVREE
Continued increasing demand for IMCIVREE, with a consistent number of new prescriptions received over the past several quarters, resulting in ongoing growth in patients on reimbursed therapy.
International Expansion
Steady global growth in the number of patients on paid therapy, with notable contributions from France, Germany, and Italy.
Financial Position
Rhythm remains well-capitalized with a projected cash runway into 2027.
RYTM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RYTM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $62.71 | $64.63 | +3.06% |
Feb 26, 2025 | $51.03 | $53.32 | +4.49% |
Nov 05, 2024 | $56.25 | $62.65 | +11.38% |
Aug 06, 2024 | $44.03 | $44.04 | +0.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Rhythm Pharmaceuticals Inc (RYTM) report earnings?
Rhythm Pharmaceuticals Inc (RYTM) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Rhythm Pharmaceuticals Inc (RYTM) earnings time?
Rhythm Pharmaceuticals Inc (RYTM) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RYTM EPS forecast?
RYTM EPS forecast for the fiscal quarter 2025 (Q2) is -0.64.